• Independence Day
  • About BreezyScroll
  • Privacy & Policy
  • Contact Us
Friday, November 20, 2026
BreezyScroll
  • Home
  • Breezy Stories
  • Technology
  • Gaming
  • Entertainment
  • Lifestyle
  • World
  • Money
  • Sports
  • Breezy Explainer
  • Dussehra
No Result
View All Result
  • Home
  • Breezy Stories
  • Technology
  • Gaming
  • Entertainment
  • Lifestyle
  • World
  • Money
  • Sports
  • Breezy Explainer
  • Dussehra
No Result
View All Result
BreezyScroll
No Result
View All Result

Home  /  Science  /  A diabetes drug could be a game-changer for obesity: Study

A diabetes drug could be a game-changer for obesity: Study

by KS Arpitha
June 6, 2022
in Health, Science
Reading Time: 3 mins read

A new study reveals that tirzepatide, a type 2 diabetes drug resulted in dramatic weight loss. The drug offers new hope for diabetic patients struggling with obesity.

Diabetes drug leads to unprecedented weight loss

According to a new study, tirzepatide, a drug approved for treating Type 2 diabetes is also effective for treating obesity. The drug works on two hormones involved in controlling blood sugar levels and sending a fullness signal from the gut to the brain. Published in The New England Journal of Medicine, the study reveals people who took this diabetes drug were losing weight. The new study focused on non-diabetic people with obesity and found more weight loss. Moreover, the study lead to about 21 percent of body weight loss with the highest recommended dose. 

“Nothing has provided that kind of weight loss except surgery. We’ve not had tools like this. I think it’s really exciting,” stated Dr. Robert Gabbay. Dr. Gabbay is the chief scientific and medical officer of the American Diabetes Association (ADA). Moreover, according to Jeff Emmick, most of the trial participants did not experience major side effects. Emmick is the Vice President of Lilly, the drug giant, and manufacturer of tirzepatide. 15 percent of the participants dropped from the 72-week-long trial. About a third dropped out as they were experiencing gastrointestinal side effects, Additionally, 26 percent receiving the placebo dropped out of the study. According to Emmick, they may be frustrated by the lack of weight loss.

ADVERTISEMENT

More on tirzepatide trial

The US Food and Drug Administration (FDA) on May 13, approved the drug under the trade name Mounjaro for treating type 2 diabetes. Currently, the diabetes drug is not approved for weight loss. However, the firm hopes to change the scenario after finishing other trials and better understand its action on various people. According to Dr. Gabbay, over 15 to 20 percent weight loss has more potential in changing treatment for diabetes. “That is a potential game-changer in how we think about therapy for people with Type 2 diabetes,” he added.

The previous study for tirzepatide in people suffering from diabetes revealed remission in patients while taking the drug. “What is not known, is whether remission achieved this way will reduce the typical complications of diabetes, which can also include cardiovascular disease, nerve and kidney damage, and limb amputations,” added Gabbay. Additionally, “It’s also unclear whether tirzepatide will provide the cardiovascular benefits that semaglutide does. It would be helpful to run a head-to-head trial between the two drugs to see whether there are any differences in their health benefits,” asked Dr. David Rind. Dr. Rind, a primary health care provider is also the chief medical officer for Clinical and Economic Review.

Tags: DiabetesWeight loss
ShareTweetShareSend
ADVERTISEMENT

Recent Articles

Older men and women with arms outstretched during an exercise class in a community hall

Higher BMI After 65 Tracked Lower Death Risk. Waist Didn’t

November 18, 2026
The Pitt Building, the Gothic-revival home of Cambridge University Press on Trumpington Street in Cambridge

Cambridge Dictionary’s 2026 Word of the Year Is ‘Human’

November 18, 2026
A limousine and a police car at the entrance of the Shenzhen International Exchange Center beside an APEC China 2026 sign

Shenzhen Offered One Household $1,500 to Leave During APEC

November 18, 2026
Two men stand in the plant-filled ground-floor lobby of Anthropic's San Francisco office, with wooden seating booths on either side

Anthropic Researcher Says AI Will Make Humans Unemployable

November 18, 2026
BreezyScroll Logo

BreezyScroll is a global content platform that provides a unique experience of enhancing the knowledge quotient for its audience by providing the latest news and updates from various categories such as politics, sports, entertainment, technology, and more.
The platform aims to provide a concise and easy-to-read format for its users. BreezyScroll covers news stories from around the world, majorly the United States. The platform was launched in 2021 and has become one of the fastest-growing content companies in the US.

Follow Us

Browse by Category

  • Africa
  • Alaska
  • Animals
  • Asia
  • Athletics
  • Australia
  • Auto
  • Basketball
  • Bollywood
  • Brand
  • Breezy Explainer
  • Breezy Feature
  • Breezy Soul
  • Business
  • Canada
  • Chess
  • China
  • Cricket
  • DIY
  • Education
  • Entertainment
  • Environment
  • EPL
  • Europe
  • Exclusive Interview
  • Exclusive Review
  • Football
  • Gaming
  • Health
  • Hollywood
  • India
  • International
  • K Pop
  • Law
  • Lifestyle
  • Middle East
  • Money
  • NFL
  • North America
  • OTT
  • Paris Olympics
  • Pets
  • Russia
  • Science
  • South America
  • Space
  • Sports
  • Startup
  • Technology
  • Tennis
  • Tennis
  • The Achievers
  • The US
  • Travel
  • UK
  • UK
  • Uncategorized
  • World
  • WWE

Trending Topics

AI Apple Artificial Intelligence Australia Biden California Canada ChatGPT China Climate Change Donald Trump Elon Musk FBI Featured Florida Google IPL Iran Japan Joe Biden Mars Meta Moon NASA NBA Netflix New York North Korea Ohio OpenAI Putin Russia Russia-Ukraine crisis South Korea SpaceX Taliban Tesla Texas TikTok Trump Twitter UFO UK Ukraine Virat Kohli

No Result
View All Result
  • About BreezyScroll
  • Breezy Stories
  • Contact Us
  • Corrections Policy
  • Editorial Policy and Standards
  • Masthead
  • Privacy Policy
  • World News – Latest News Today | BreezyScroll

© 2024 · BreezyScroll.com

No Result
View All Result
  • Home
  • Breezy Stories
  • Technology
  • Gaming
  • Entertainment
  • Lifestyle
  • World
  • Money
  • Sports
  • Breezy Explainer
  • Dussehra

© 2024 · BreezyScroll.com

Go to mobile version